EP Patent

EP3308773A1 — Formulations of cysteamine and cysteamine derivatives

Assigned to Recordati Industria Chimica e Farmaceutica SpA · Expires 2018-04-18 · 8y expired

What this patent protects

Oral cysteamine formulation consisting of dry layered lipid matrix microparticles useful for treating cystinosis and neurodegenerative disorders are described.

USPTO Abstract

Oral cysteamine formulation consisting of dry layered lipid matrix microparticles useful for treating cystinosis and neurodegenerative disorders are described.

Drugs covered by this patent

Patent Metadata

Patent number
EP3308773A1
Jurisdiction
EP
Classification
—
Expires
2018-04-18
Drug substance claim
No
Drug product claim
No
Assignee
Recordati Industria Chimica e Farmaceutica SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.